SCHEMBL20364375

SCHEMBL20364375

Cc1cccc(Cn2cnc(NC(=O)c3cc4c(s3)CCNC4)c2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 2/20 0.42
ITGB3 P05106 5/20 0.40
ITGA2B P08514 5/20 0.40
NPC1 O15118 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 2/20 0.39
RIPK1 Q13546 3/20 0.39
TAS2R8 Q9NYW2 1/20 0.39
TPSAB1 Q15661 1/20 0.39
TPSD1 Q9BZJ3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20364377 0.93 NPC1 (0.40) ITGB3ITGA2BNPC1ALDH1A1MAPT
SCHEMBL20367312 0.87 KDM4C (0.43) PNMTITGB3ITGA2BNPC1ALDH1A1
SCHEMBL20364378 0.84 RIPK1 (0.38) MAPTRXFP1RIPK1TAS2R8CDK5
SCHEMBL20364380 0.82 TAS2R8 (0.54) MAPTSMN1; SMN2RIPK1TAS2R8
SCHEMBL20364379 0.82 TAS2R8 (0.54) ITGB3ITGA2BMAPTTAS2R8
SCHEMBL20364372 0.82 TAS2R8 (0.41) RIPK1TAS2R8CDK5CDK5R1
SCHEMBL20364373 0.81 TAS2R8 (0.41) MAPTRIPK1TAS2R8CDK5CDK5R1
SCHEMBL20367479 0.81 KDM4C (0.43) ITGB3ITGA2BNPC1ALDH1A1MAPT
SCHEMBL20364376 0.80 TAS2R8 (0.40) RXFP1RIPK1TAS2R8CDK5CDK5R1
SCHEMBL20364374 0.79 TAS2R8 (0.44) MAPTRIPK1TAS2R8CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE NR0B1, NR2E1, NR0B2 PNMT 4302/4885ITGB3 981/4885ITGA2B 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.